1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - General
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.

Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.

300357.SZ
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.CN flagShenzhen Stock Exchange
22.90
CNY
-1.34
- -
11.99BMarket Cap
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd.
300357.SZ
(Shenzhen Stock Exchange)

Recent

price

22.90

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
- -
0.22
0.32
0.41
0.46
0.51
0.6
0.74
0.96
1.22
1.22
1.54
1.71
1.62
1.77
2.03
1.87
Revenue per Share
- -
0.08
0.12
0.15
0.19
0.23
0.25
0.36
0.44
0.57
0.53
0.65
0.67
0.59
0.61
0.73
0.66
Basic EPS, GAAP
- -
0.03
0.07
0.09
0.12
0.16
0.17
0.24
0.28
0.25
0.36
0.46
0.33
0.33
0.28
0.58
-0.25
Free Cash Flow per Basic Share
- -
- -
- -
- -
0.06
0.09
0.11
0.08
0.12
0.14
0.18
0.16
0.2
0.2
0.19
0.22
0.29
Dividend per Share
- -
0.26
0.37
0.5
0.59
0.69
0.81
1.05
1.57
1.94
2.24
2.7
3.09
3.41
3.73
4.24
3.95
Book Value per Share
- -
0.24
0.36
0.5
0.95
1.06
1.18
1.43
1.67
2.27
2.59
3.09
3.51
4.04
4.35
4.86
4.56
Tangible Book Value per Share
- -
471
465
467
520
523
523
524
524
524
524
524
524
524
524
524
524
Basic Weighted Avg Shares
59
103
148
194
240
267
312
386
501
639
636
808
896
848
925
1,062
980
Sales/Revenue/Turnover
30.16
41.06
41.48
42.28
45.02
48.18
48.06
53.7
50.64
49.79
46.32
45.32
46.34
37
35.94
39.01
36.9
Operating Margin (%)
3
3
3
4
4
4
6
6
7
10
15
25
26
38
51
56
- -
Depreciation Expense
18
37
54
71
100
118
129
186
233
298
278
338
349
310
318
381
346
Net Income, GAAP
11.02
15.18
15.19
15.11
16.26
15.01
14.91
15.01
15.06
15.36
16.39
16.97
15.81
14.58
16.63
14.93
15.72
Effective Tax Rate (%)
31.02
36.12
36.45
36.45
41.57
44.11
41.4
48.27
46.51
46.66
43.77
41.85
38.92
36.57
34.34
35.86
35.25
Profit Margin (%)
41
78
127
183
431
460
503
614
724
990
1,110
1,234
1,374
1,393
1,469
1,617
1,503
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
5
2
12
21
8
9
11
LT Debt
90
128
181
252
514
583
656
801
995
1,352
1,528
1,797
2,027
2,304
2,459
2,712
2,566
Total Equity
14.9
29.78
32.12
31.82
23.42
19.86
20.64
24.03
23.61
22.73
16.99
17.87
17.83
12.09
11.4
13.47
12.1
Return on Invested Capital (%)
17.38
32.29
35.38
34.65
35.44
33.9
31.92
37.6
32.08
31.21
24.42
25.6
22.91
17.87
16.39
17.86
17.1
Return on Capital (%)
18.24
34.9
36.4
34.64
36.79
35.22
32.87
38.26
33.91
32.4
25.44
26.16
23.03
18.23
16.99
18.25
17.69
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
ST Debt
18
9
10
LT Borrowings
- -
- -
- -
LT Finance Leases
8
1
11
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
524
524
524
Market Capitalization
10,636
11,141
10,806

Working Capital

FRC

•

in mil. unless spec.
Dec'24
Mar'25
Jun'25
Total Current Assets
1,651
1,610
1,684
Cash, Cash Equivalents & STI
1,315
1,286
1,363
Accounts Receivable, Net
153
170
192
Inventories
58
57
56
Total Current Liabilities
183
84
180
Payables & Accruals
- -
- -
- -
ST Debt
18
9
10
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
16.88%
12.21%
10.29%
Free Cash Flow
19.11%
18.95%
110.32%
Net Income, GAAP
13.61%
7.17%
19.86%
Sales/Revenue/Turnover
15.39%
11.29%
14.81%
Total Cash Common Dividend
11.57%
5.09%
18.32%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
216
213
301
195
925
2025
228
256
209
- -
1,062
2026
253
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.15
- -
- -
- -
0.61
2025
0.14
- -
- -
- -
0.73
2026
0.23
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.19
2025
0.1
- -
- -
- -
0.22
2026
0.1
- -
- -
- -
- -
Similar Companies
Roche Holding AG (0QQ6.L)
PT Kalbe Farma Tbk. (PTKFF)
NGL Fine-Chem Limited (NGLFINE.BO)
Biogen Inc. (BIIB.SW)
Citius Oncology, Inc. (CTOR)
Sanofi (SNW.DE)
Business
Zhejiang Wolwo Bio-Pharmaceutical Co., Ltd. engages primarily in the research, development, manufacture, and sale of bio-pharmaceutical products. Its core offerings include recombinant protein drugs, monoclonal antibodies, small molecule chemical drugs, and innovative biological therapeutics. The company provides products for various therapeutic areas such as oncology, autoimmune diseases, and infectious diseases. Wolwo Bio-Pharmaceutical operates its business across China and extends export activities internationally. Founded in 2001, the company is headquartered in Zhejiang, China. In recent years, Zhejiang Wolwo Bio-Pharmaceutical has made strategic advancements including new product launches in innovative biologics and expansions in research collaborations to enhance its pharmaceutical pipeline. The company has also pursued partnerships and alliances aimed at accelerating drug development and market penetration. There have been no recent reports of rebranding or major structural reorganizations, but operational expansions and product diversification have been key focus areas within the last two years. The company operates within the pharmaceutical and biotechnology industry, targeting hospitals, medical institutions, and healthcare providers primarily in the Chinese market, with growing international outreach. Its business segments include biologics manufacturing, chemical drug production, and contract research services. Zhejiang Wolwo Bio-Pharmaceutical maintains subsidiaries focused on specific therapeutic segments to streamline development and commercialization efforts. This comprehensive positioning reflects Zhejiang Wolwo Bio-Pharmaceutical’s ongoing commitment to advancing biopharmaceutical innovation and expanding its product portfolio in both domestic and international markets.